Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CAR-T cell therapies - Alaunos Therapeutics

Next Previous
Drug Profile

Research programme: CAR-T cell therapies - Alaunos Therapeutics

Alternative Names: ACT-based immunotherapy - Alaunos Therapeutics; Adoptive cell transfer-based immunotherapy - Alanuos Therapeutics; CAR-T cell therapeutics - Alaunos Therapeutics; Cetux-CAR T cells - Alaunos Therapeutics; Nimo-CAR T cells - Alaunos Therapeutics; Non-viral adoptive cellular cancer immunotherapies - Alaunos Therapeutics

Latest Information Update: 28 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intrexon Corporation; ZIOPHARM Oncology
  • Developer Alaunos Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Brain cancer; Cancer; Haematological malignancies

Most Recent Events

  • 28 Nov 2022 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
  • 28 Nov 2022 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
  • 26 Jan 2022 ZIOPHARM Oncology is now called Alaunos Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top